US Treasury Hits Back On Inversions; Will Pfizer Fold?

Treasury announced new regulations aimed at blocking tax-motivated deals, leaving the largest mega-deal in the history of pharma hanging in the balance.

The Pfizer Inc./Allergan PLC merger story has taken another turn, but is it a detour or a possible derailment? The US Department of the Treasury announced new actions after market close April 4 aimed at ending tax-motivated M&A, a big driver of Pfizer’s ambition to buy Allergan.

It was not immediately clear what – if any – impact the latest announcement might have on the planned merger....